Veeva Systems Inc., a California-based company that makes cloud software solutions for the life sciences industry, has filed an amended Form S-1 with the Securities and Exchange Commission for an initial public offering (IPO) of 13 million Class A shares priced between $12 and $14 a share.
Selling stockholders are offering 3.33 million shares and the rest are being offered by the company. The underwriters have an overallotment option on an additional 1.96 million shares.
The company has two classes of common stock that are priced equally, but Class B shares are entitled to 10 votes each while Class A shares are entitled to one vote per share. After the offering, holders of Class B shares will hold about 98.5% of the voting power of outstanding shares, and the company�� officers, directors and their affiliates will hold about 74% of the voting power in the company.
Veeva plans to use its share of the proceeds, estimated at $138.3 million if the underwriters��options are taken and the shares are priced at the mid-point of the estimated range, for general corporate purposes and working capital. In its filing the company said, “[W]e do not currently have specific planned uses of the proceeds. The amount of proceeds we use for the purposes above, if any, will depend on the level of cash generated from our operations.”
5 Best Japanese Stocks To Buy Right Now: ZIOPHARM Oncology Inc(ZIOP)
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company's clinical programs include Palifosfamide, a DNA cross-linker, which is in a phase III clinical trial for the treatment of metastatic soft tissue sarcoma in the front-line setting. ZIOPHARM is also developing Palifosfamide in combination with etoposide and carboplatin in phase I clinical trial to determine safety for initiating a pivotal, adaptive phase III trial in front-line. In addition, the company, in partnership with Intrexon Corporation, is developing DNA-based therapeutics (synthetic biology) that include two phase 1 clinical-stage product candidates, both of which are DNA IL-12 to be turned on/off by an oral activator ligand. Further, it is developing Indibulin, an oral tubulin binding agent, which is in Phase 1/2 for metastatic breast cancer; and Darinaparsin , a mitochondrial- and hedgehog-targeted agent that is in a solid tumor phase I study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. The company was founded in 2003 and is headquartered in New York City, New York.
Advisors' Opinion:- [By James E. Brumley]
Back on July 16th, I pointed out ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was a budding superstar. Though I suggested waiting for the stock to cool off before stepping into it (and it did cool off, by the way), ZIOP has since walked its way above the key line in the sand that was acting like a ceiling then. Though there's still one more hurdle shares need to clear before being a "must-have" stock, the heavy lifting's been done.
- [By James E. Brumley]
Four months ago, you could barely give your shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) away. The company announced s on Tuesday, March 26th, that its sarcoma drug Palifosfamide had failed to meet its Phase 3 goals. Shares of ZIOP plunged from $5.13 to $1.82 in a mere day, and were trading as low as $1.51 a week and a half later.
- [By James E. Brumley]
Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.
- [By John Udovich]
Biotech in general has been one of the market�� hottest sectors this year thanks to plenty of mostly good news�along with�new IPOs while small cap biotech stocks Delcath Systems (NASDAQ: DCTH), ZIOPHARM Oncology Inc (NASDAQ: ZIOP), Recro Pharma (NASDAQ: REPH), TetraLogic Pharmaceuticals (NASDAQ: TLOG)�and TNI BioTech (OTCMKTS: TNIB) have also produced their share of news�this week or in recent weeks. Just consider the following:
Top 5 Life Sciences Companies To Buy Right Now: Aflac Incorporated(AFL)
Aflac Incorporated, through its subsidiary, American Family Life Assurance Company of Columbus (Aflac), provides supplemental health and life insurance. The company offers various voluntary supplemental insurance products, including cancer plans, general medical indemnity plans, medical/sickness riders, care plans, living benefit life plans, ordinary life insurance plans, and annuities in Japan. It also provides loss-of-income products, such as life and short-term disability plans; and products designed to protect individuals from depletion of assets, which comprise hospital indemnity, fixed-benefit dental, vision care, accident, cancer, critical illness/critical care, and hospital intensive care plans in the United States. The company sells its products through sales associates and brokers, affiliated corporate agencies, independent corporate agencies, and individual agencies. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.
Advisors' Opinion:- [By Dividend]
AFLAC (AFL) has a market capitalization of $27.40 billion. The company employs 8,673 people, generates revenue of $25.364 billion and has a net income of $2.866 billion. AFLAC�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $5.747 billion. The EBITDA margin is 22.66 percent (the operating margin is 16.96 percent and the net profit margin 11.30 percent).
- [By Dan Caplinger]
Ask most people about Aflac (NYSE: AFL ) , and they'll automatically start talking about the company's duck commercials. But those who've focused more on Aflac stock than on its advertising have been richly rewarded lately, and with new efforts to foster growth in the insurance company's largest market, Aflac has huge potential to cash in on improving conditions among its customer base.
Top 5 Life Sciences Companies To Buy Right Now: Unit Corporation(UNT)
Unit Corporation, together with its subsidiaries, engages in the contract drilling, oil and natural gas, and mid-stream businesses in the United States. The company?s Contract Drilling segment engages in land contract drilling of onshore oil and natural gas wells for oil and natural gas companies in Oklahoma, Texas, Louisiana, Wyoming, Colorado, Utah, Montana, and North Dakota. Its Oil and Natural Gas segment is involved in the acquisition, exploration, development, and production of oil and natural gas properties located primarily in Oklahoma, Texas, Louisiana, and North Dakota, as well as in Arkansas, New Mexico, Wyoming, Montana, Alabama, Kansas, Mississippi, Michigan, Colorado, Pennsylvania, and a small portion in Canada. As of December 31, 2011, this segment had approximately 121 gross proved undeveloped wells. The company?s Mid-Stream segment buys, sells, gathers, processes, and treats natural gas. It operates 3 natural gas treatment plants, 10 operating processing plants, 35 active gathering systems, and 934 miles of pipeline in Oklahoma, Texas, Kansas, Pennsylvania, and West Virginia. The company operates a fleet of 127 drilling rigs. Unit Corporation was founded in 1963 and is based in Tulsa, Oklahoma.
Advisors' Opinion:- [By Robert Rapier]
Having said that, I can’t find anything in the article archives about Unit Corp. (NYSE: UNT). Unit describes itself as a diversified energy company engaged in the exploration for and production of oil and natural gas, the acquisition of producing oil and natural gas properties, the contract drilling of onshore oil and natural gas wells, and the gathering and processing of natural gas.
Top 5 Life Sciences Companies To Buy Right Now: SPDR DB International Government Inflation-Protected Bond ETF (WIP)
SPDR DB International Government Inflation-Protected Bond ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the DB Global Government ex-US Inflation-Linked Bond Capped Index (the Index). The Index measures the performance of the inflation-linked government bond markets of developed and emerging market countries outside of the United States. Inflation protected public obligations of the inflation-linked government bond markets of developed and emerging market countries, commonly known in the United States as treasury inflation-protected securities (TIPS), are securities issued by such governments that are designed to provide inflation protection to investors. The Fund uses a passive management strategy to track the Index. The Fund�� investment advisor is SSgA Funds Management, Inc. Advisors' Opinion:- [By Richard Stavros]
With respect to inflation protected bonds, though TIPS should be a part of every portfolio. However, we believe the SPDR DB International Government Inflation-Protected Bond (WIP) offers greater protection than TIPS.
No comments:
Post a Comment